TARSUS PHARMACEUTICALS INC's ticker is TARS and the CUSIP is 87650L103. A total of 45 filers reported holding TARSUS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,582,669 | +81.4% | 2,621,422 | +84.4% | 2.72% | +88.8% |
| Q2 2023 | $25,685,096 | +143657.2% | 1,421,422 | 0.0% | 1.44% | +22.3% |
| Q1 2023 | $17,867 | -29.8% | 1,421,422 | -18.1% | 1.18% | -30.9% |
| Q4 2022 | $25,456 | -99.9% | 1,736,422 | -11.9% | 1.70% | -27.8% |
| Q3 2022 | $33,751,000 | +23.3% | 1,971,422 | +5.1% | 2.36% | +14.0% |
| Q2 2022 | $27,375,000 | +18.3% | 1,875,000 | +36.3% | 2.07% | +16.5% |
| Q1 2022 | $23,144,000 | -26.7% | 1,375,982 | -1.9% | 1.78% | -5.4% |
| Q4 2021 | $31,575,000 | +1.4% | 1,403,331 | -2.9% | 1.88% | +48.5% |
| Q3 2021 | $31,136,000 | -29.0% | 1,444,831 | -4.6% | 1.26% | -15.2% |
| Q2 2021 | $43,884,000 | -20.6% | 1,514,269 | -11.7% | 1.49% | +21.1% |
| Q1 2021 | $55,251,000 | -21.0% | 1,714,269 | 0.0% | 1.23% | -26.1% |
| Q4 2020 | $69,965,000 | – | 1,714,269 | – | 1.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,084,370 | $30,432,000 | 4.62% |
| Vivo Capital, LLC | 2,312,368 | $33,761,000 | 3.39% |
| Frazier Life Sciences Management, L.P. | 1,787,527 | $26,098,000 | 2.46% |
| Cormorant Asset Management, LP | 1,875,000 | $27,375,000 | 2.07% |
| Sands Capital Ventures, LLC | 260,000 | $3,796,000 | 1.04% |
| Ghost Tree Capital, LLC | 120,000 | $1,752,000 | 0.91% |
| RTW INVESTMENTS, LP | 2,013,601 | $29,399,000 | 0.76% |
| COWEN AND COMPANY, LLC | 534,524 | $7,804,000 | 0.75% |
| Perceptive Advisors | 1,296,416 | $18,927,000 | 0.59% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,324,214 | $19,334,000 | 0.40% |